Vera Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 362

Employees

  • Stock Symbol
  • VERA

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $25.45
  • (As of Friday Closing)

Vera Therapeutics General Information

Description

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Contact Information

Website
www.veratx.com
Formerly Known As
CDF Therapeutics, Trucode Gene Repair
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 2000 Sierra Point Parkway
  • Suite 1200
  • Brisbane, CA 94005
  • United States
+1 (650)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 2000 Sierra Point Parkway
  • Suite 1200
  • Brisbane, CA 94005
  • United States
+1 (650)

Vera Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vera Therapeutics Stock Performance

As of 20-Nov-2026, Vera Therapeutics’s stock price is $25.45. Its current market cap is $1.84B with 72.3M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$25.45 $26.74 $25.08 - $56.05 $1.84B 72.3M 1.94M -$5.90

Vera Therapeutics Financials Summary

As of 30-Sep-2026, Vera Therapeutics has a trailing 12-month revenue of $10.3M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,904,669 3,174,603 2,379,533 554,488
Revenue 10,277 0 0 0
EBITDA (428,190) (316,094) (165,130) (100,161)
Net Income (415,313) (299,615) (152,148) (95,990)
Total Assets 465,752 734,733 655,681 175,546
Total Debt 76,791 77,306 54,638 53,708
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vera Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vera Therapeutics‘s full profile, request access.

Request a free trial

Vera Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Vera Therapeutics‘s full profile, request access.

Request a free trial

Vera Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transfo
Biotechnology
Brisbane, CA
362 As of 2026

Morrisville, NC
 

Lexington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vera Therapeutics Competitors (60)

One of Vera Therapeutics’s 60 competitors is TG Therapeutics, a Corporation company based in Morrisville, NC.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
TG Therapeutics Corporation Morrisville, NC
Aldeyra Therapeutics Formerly VC-backed Lexington, MA
Omeros Formerly VC-backed Seattle, WA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
You’re viewing 5 of 60 competitors. Get the full list »

Vera Therapeutics Patents

Vera Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026076069-A1 Methods related to the treatment of kidney disease Pending 01-Oct-2024
WO-2022132929-A2 Multispecific antibody molecules and uses thereof Inactive 16-Dec-2020
WO-2022132929-A3 Multispecific antibody molecules and uses thereof Inactive 16-Dec-2020
AU-2021288699-A1 Dosing of polyomavirus neutralizing antibodies Pending 12-Jun-2020
CA-3186736-A1 Dosing of polyomavirus neutralizing antibodies Pending 12-Jun-2020 C07K16/084
To view Vera Therapeutics’s complete patent history, request access »

Vera Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vera Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Vera Therapeutics‘s full profile, request access.

Request a free trial

Vera Therapeutics Investments & Acquisitions (3)

Vera Therapeutics’s most recent deal was a Corporate Asset Purchase with Stanford University (Global Rights to Novel VT-109) for . The deal was made on 13-Jan-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Stanford University (Global Rights to Novel VT-109) 13-Jan-2025 Corporate Asset Purchase Buildings and Property
Amplyx Pharmaceuticals (Monoclonal Antibody MAU868) 17-Dec-2021 Corporate Asset Purchase Drug Discovery
PNA Innovations 26-Apr-2021 Merger/Acquisition Discovery Tools (Healthcare)
To view Vera Therapeutics’s complete investments and acquisitions history, request access »

Vera Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.59 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Vera Therapeutics’s complete esg history, request access »

Vera Therapeutics FAQs

  • When was Vera Therapeutics founded?

    Vera Therapeutics was founded in 2016.

  • Where is Vera Therapeutics headquartered?

    Vera Therapeutics is headquartered in Brisbane, CA.

  • What is the size of Vera Therapeutics?

    Vera Therapeutics has 362 total employees.

  • What industry is Vera Therapeutics in?

    Vera Therapeutics’s primary industry is Biotechnology.

  • Is Vera Therapeutics a private or public company?

    Vera Therapeutics is a Public company.

  • What is Vera Therapeutics’s stock symbol?

    The ticker symbol for Vera Therapeutics is VERA.

  • What is the current stock price of Vera Therapeutics?

    As of 20-Nov-2026 the stock price of Vera Therapeutics is $25.45.

  • What is the current market cap of Vera Therapeutics?

    The current market capitalization of Vera Therapeutics is $1.84B.

  • What is Vera Therapeutics’s current revenue?

    The trailing twelve month revenue for Vera Therapeutics is $10.3M.

  • Who are Vera Therapeutics’s competitors?

    TG Therapeutics, Aldeyra Therapeutics, Omeros, Adaptimmune Therapeutics, and Inovio Pharmaceuticals are some of the 60 competitors of Vera Therapeutics.

  • What is Vera Therapeutics’s annual earnings per share (EPS)?

    Vera Therapeutics’s EPS for 12 months was -$5.90.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process